Ran Zheng

Director/Board Member presso CARIBOU BIOSCIENCES, INC.

Patrimonio netto: - $ in data 31/03/2024

60 anni

Health Technology

Consumer Services

Posizioni attive di Ran Zheng

Società	Posizione	Inizio	Fine
CARIBOU BIOSCIENCES, INC.	Director/Board Member	24/09/2021	-
CARIBOU BIOSCIENCES, INC.	Independent Dir/Board Member	24/09/2021	-
Landmark Bio PBLLC	Director/Board Member	01/03/2021	-
Landmark Bio PBLLC	Chief Executive Officer	01/03/2021	-

Società	Posizione	Inizio	Fine
ORCHARD THERAPEUTICS PLC	Chief Tech/Sci/R&D Officer	18/03/2019	01/02/2021
AMGEN INC.	Corporate Officer/Principal	-	-

University of Minnesota	Graduate Degree
Beijing Forestry University	Undergraduate Degree

Distribuzione geografica

Posizioni

Settori

Health Technology	4
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
AMGEN INC.	Health Technology
CARIBOU BIOSCIENCES, INC.	Health Technology

Aziende private	2
Orchard Therapeutics Plc Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.	Health Technology
Landmark Bio PBLLC

Aziende private

Health Technology

Landmark Bio PBLLC